Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma
Antonino Carbone, Annunziata Gloghini, Carmelo Carlo‐Stella
Abstract
Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/immune cells. Follicular lymphoma, mediastinal gray zone lymphoma, and diffuse large B-cell lymphomas may show a TME containing inflammatory/immune cells, but the TMEs are quite different. In B-cell lymphomas and cHL, programmed cell death 1 (PD-1)-PD ligand 1 pathway blockade drugs differ in their effectiveness among patients with refractory/relapsed disease. Further research should explore innovative assays that could reveal which molecules influence sensitivity or resistance to therapy in an individual patient.
Topics & Concepts
Tumor microenvironmentLymphomaImmune checkpointCancer researchFollicular lymphomaImmune systemBlockadeMedicineImmunotherapyImmunologyInternal medicineReceptorLymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCAR-T cell therapy research